Sedana Medical's Sedaconda study published in the Lancet
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the results of the company's pivotal study Sedaconda (SED001) have been published in the highly ranked scientific journal, the Lancet Respiratory Medicine.
"We are very pleased that the study is published in Lancet Respiratory Medicine. The results of the study, which is the largest in inhaled sedation, point to the efficacy and safety of isoflurane via AnaConDa as well as the benefits of the therapy, namely reduced need of opioids, increased spontaneous breathing and faster awakening. Overall, there are now strong reasons to consider inhaled sedation as a first-line therapy,” said the study's principal investigator in Germany, Associate Professor Andreas Meiser, Saarland University Medical Center, Homburg, Germany.
“The publication is a great recognition for the investigators and for Sedana Medical´s clinical trial. The publication in Lancet Respiratory Medicine, which is the leading journal in the field of intensive care and respiratory medicine, is also important in establishing inhaled sedation as a global standard therapy,” said Peter Sackey, Chief Medical Officer of Sedana Medical.
Short on the Sedaconda study
The results from the Sedaconda study demonstrate that Sedaconda (isoflurane) administered via AnaConDa, compared with intravenous propofol, reduces the need of opioids, facilitates spontaneous breathing, which improves lung function during and after ventilator treatment, and enables a faster and more predictable awakening.
The study was conducted at 23 intensive care clinics in Germany and Slovenia and included 301 mechanically ventilated patients in need of sedation. Half of the patients were treated with Sedaconda administered via AnaConDa and half with propofol. The safety profile of Sedaconda was consistent with previously known findings for isoflurane. The study results form the basis for Sedana Medical's European market approval.
For additional information, please contact:
Jens Lindberg, Acting CEO, +46 72 531 11 17
Peter Sackey, Chief Medical Officer, +46 70 771 03 64
Sedana Medical is listed on Nasdaq First North Growth Market in Stockholm.
The company's Certified Adviser is Erik Penser Bank, +46 8 463 83 00, email@example.com.
About Sedana Medical
Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient’s life during and beyond sedation. Through the combined strengths of the medical device AnaConDa and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.
Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordics, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.
Sedana Medical was founded in 2005, is listed on Nasdaq First North Growth Market (SEDANA) and headquartered in Stockholm, Sweden.